The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
If the Trump administration and Congress fail to reach a spending agreement, the White House will offer to keep the government funded at its current levels for a year, Mnuchin...Politicsread more
Resident "Fast Money" crypto expert Brian Kelly breaks down the major differences between bitcoin and Facebook's new cryptocurrency Libra.Fast Moneyread more
Oracle found revenue growth from cloud applications in its fiscal fourth quarter, which helped it surpass analysts' expectations.Technologyread more
Federal Reserve Chairman Jerome Powell said on Wednesday that Facebook spoke to the central bank about the digital currency called LibraThe Fedread more
The vote makes Mexico the first of the three countries to win legislative approval for the trade agreement.Politicsread more
Walgreens Boots Alliance shareholders have instructed the company to explain how it's monitoring and managing risks related to the opioid crisis, according to preliminary results announced Friday at Walgreens' annual shareholders meeting.
The measure requires Walgreens to prepare a report by June 30 detailing any changes the company has made to its corporate governance since 2012 in response to the opioid crisis. Investors want more specifics, including how Walgreens' board oversees opioid-related programs and whether executive bonuses consider any opioid-related objectives like promoting ethical conduct.
Investors for Opioid Accountability, a coalition that includes state treasurers, comptrollers, asset managers, labor funds and faith-based groups, submitted the proposal. It has filed similar ones with nearly a dozen companies, including drug distributors AmerisourceBergen and Cardinal Health and drug companies Johnson & Johnson and Pfizer.
Walgreens' board opposed the proposal, saying it already discloses how it's handling the issue. Preliminary results showed shareholders voted in favor of the measure, though the company said final results will be released in a filing with the Securities and Exchange Commission. CEO Stefano Pessina is Walgreens' largest shareholder, holding about 15 percent of the company's stock, according to FactSet.
Drugmakers, distributors and pharmacies have all come under scrutiny for their role in the crisis that has killed scores of Americans. Lax prescribing and monitoring of prescription painkillers is widely seen as fueling opioid addiction. Now these companies face lawsuits from thousands of state and local governments.
Two influential proxy advisory firms, Glass Lewis and Institutional Shareholder Services, recommended shareholders vote in favor of the proposal. In its analysis, ISS said despite a proliferation of lawsuits, subpoenas and investigations related to the opioid crisis, Walgreens "does not seem to have taken steps at the board level related specifically to managing risks stemming from the opioid epidemic."
Glass Lewis in its analysis said a "more thorough discussion is warranted at this time."
They cite the immediate financial and legal risks to the company, as well as the additional threats. Walgreens owns about one-fourth of AmerisourceBergen, which is also embroiled in opioid litigation.